The filing introduces a product-quality issue the market was not previously expecting. SI-BONE initiated a voluntary recall of 98 iFuse TORQ implants after packaging failed to meet sterile-barrier acceptance criteria. 〔0〕 There is no clean published consensus benchmark for a recall, so the relevant comparison is against the prior assumption of uninterrupted product availability and no remediation cost: this is a new negative.
| Item | Filing detail |
|---|---|
| Distributed implants recalled | 98 (Recall disclosure) |
| Already implanted | 2 (Recall disclosure) |
| Implants expected to be repackaged and re-sterilized | Approximately 3,900 (Recall disclosure) |
| Estimated gross charge | Up to approximately $150,000 (Recall disclosure) |
| Expected revenue impact | None otherwise expected in Q3 (Recall disclosure) |
The immediate financial damage looks contained, but the operational scope is much larger than the headline recall count. Only 98 implants had left company control, while approximately 3,900 implants may require repackaging and re-sterilization. 〔1〕 The estimated charge of up to $150,000 is modest in absolute terms, and the company says revenue should not otherwise be affected. 〔2〕
The main uncertainty is regulatory and liability exposure, not the disclosed charge. Two recalled implants were already implanted, although no infections or adverse events had been reported as of the filing date. 〔3〕 SI-BONE has requested Class II classification from the FDA, but the agency could classify the recall differently, expand its scope, or identify additional remediation requirements; the company also has not secured reimbursement from the tube manufacturer. Net, the filing is a mild negative: limited near-term financial impact, offset by a new product-quality and regulatory overhang that remains unresolved.
Read the original 8-K on SEC EDGAR ↗